Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia.

摘要: Animal studies, experimental models on cell lines, and epidemiological case-control studies have all suggested the possibility that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors a beneficial effect bone metabolism. However, are not prospective in nature based either measurement of mineral density or fracture risk. They also differ recruitment criteria, definition statin exposure, outcome assessment. We performed first study using specific biochemical markers 17 hypercholesterolaemic non-osteoporotic subjects treated with therapeutic dose simvastatin 20 mg daily for 4 weeks. Our results show serum osteocalcin concentration increased significantly (p-value < 0.05) weeks after therapy, whereas other including bone-specific alkaline phosphatase activity, urine deoxypyridinoline, cross-linked N-telopeptides type I collagen did any significant changes. data support causes metabolism as reflected by an increase concentration. This added statins could potentially allow to become effective anabolic agent treatment osteoporosis. urge priority should be given randomised controlled re-evaluate this group drugs.